Melissa BOU JAOUDEH

Innovative Product Development Officer

[Melissa BOU JAOUDEH @Melissa_MBJ]

I am deeply honored to receive the Martín Villard Basic Research Award. It is truly humbling and motivating to be recognized by the awards committee, to whom I am grateful.
I am also grateful to my team.
@DesmazesLacroix @CRCordeliers
#grifols #hemostasisawards #PhD #sorbonne

[Melissa BOU JAOUDEH @Melissa_MBJ]

https://t.co/zfmHF6YmCb

[Melissa BOU JAOUDEH @Melissa_MBJ]

Happy to share with you our newly published brief report in the Journal of Thrombosis and Haemostasi!

[JTH @JTHjournal]

IgG-✂️enzyme (IdeS), tool to ease management breakthrough bleeds or programmed major surgeries in inhibitor-➕ PwHA 💊emicizumab prophylaxis.
@Melissa_MBJ
@CRCordeliers
@Inserm        
@CNRS
@INSB_CNRS
@DesmazesLacroix
@InsermU1176
@Sorbonne_Univ_
https://t.co/jwMS0eLv8G

[JTH @JTHjournal]

IgG-✂️enzyme (IdeS), tool to ease management breakthrough bleeds or programmed major surgeries in inhibitor-➕ PwHA 💊emicizumab prophylaxis.
@Melissa_MBJ
@CRCordeliers
@Inserm        
@CNRS
@INSB_CNRS
@DesmazesLacroix
@InsermU1176
@Sorbonne_Univ_
https://t.co/jwMS0eLv8G

[JTH @JTHjournal]

Engineered monovalent IgG (FabFc) foster for the transplacental delivery of matenal FVIII, thus paving the way towards in utero replacement therapy and induction of #immune tolerance.

@CRCordeliers @Inserm @CNRS @INSB_CNRS @DesmazesLacroix
https://t.co/oRUtASDUlv

[Melissa BOU JAOUDEH @Melissa_MBJ]

Session Poster
@cfh_2023

[Melissa BOU JAOUDEH @Melissa_MBJ]

Our paper is officially published.

Enjoy the read!

⬇️⬇️

The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice | Haematologica https://t.co/KiW2wKAwof

[Melissa BOU JAOUDEH @Melissa_MBJ]

Last Friday, I had the opportunity to present my work at the CRC scientific day, where Ph.D. students, researchers, and post-docs presented their work in various fields of research.

#CRCordeliers #PhD #Immunology #Haematology

[Paul Batty @paul_batty1]

Great presentation from @MelissaBouJoude at #ISTH2022 investigating usage of IdeS in a mouse model with a human FVIII monoclonal inhibitor demonstrating restoration of fviii haemostatic function and bleeding tendency

[VJHemOnc @VJHemOnc]

Melissa Bou Jaoudeh (@melimbj) talks on the therapeutic potential of IdeS in patients with hemophilia A with inhibitors.

🎥: https://t.co/kYazMGkE8E

@isth #ISTH2022 #Hemophilia #RareDiseases #HemOnc

[médecine/sciences @ms_MedSci]

L’utilisation de protéines thérapeutiques se heurte parfois à l’apparition d’anticorps #neutralisants. Découvrez l’origine de la réponse immunitaire neutralisante contre le facteur VIII #pro-coagulant. https://t.co/sgEZP0aUpp #openaccess @melimbj @aditiztweet @CRCordeliers

[VJHemOnc @VJHemOnc]

We just spoke to @melimbj (@Sorbonne_Univ_) about her research on hemophilia with inhibitors 💡

Visit 👉https://t.co/O9p0vDBrzw👈 to hear about the latest research updates from #ISTH2022!

@isth #Hemophilia #RareDiseases #HemOnc #BleedingDisorders #Thrombosis #Hemostasis

[Melissa BOU JAOUDEH @Melissa_MBJ]

Amazing experience presenting my work at the ISTH 2022 Congress in London! #ISTH2022 #hemophilia

[Gavin Ling @DrGavinL]

@Melissa_MBJ great talk on the use of ldeS in temporarily removing neutralising FVIII antibodies to dose FVIII - helpful background on its future therapeutic uses, also being trialed in #genetherapy. #hemophilia #ISTH2022

[Melissa BOU JAOUDEH @Melissa_MBJ]

@DrGavinL The majority of IdeS will be cleared from the circulation within 24-48 hr, allowing rapid re-administration of emicizumab for prophylaxis.

[Melissa BOU JAOUDEH @Melissa_MBJ]

@DrGavinL Thank you!

[Melissa BOU JAOUDEH @Melissa_MBJ]

Ce fut un réel plaisir de participer au Congrès Français d'Hémostase qui s'est tenu à la Cité Mondiale de Bordeaux. J'ai eu l'occasion de présenter mes résultats sur l'élimination des IgG neutralisantes anti-FVIII par IdeS #CFH2022

[MHEMO @FiliereMHEMO]

🍇 #CFH2022🍇
Les communications orales continuent "Anomalies hémorragiques de l’hémostase"
Modérateurs : C Ternisien, C Négrier
Présentation "Elimination des IgG anti-FVIII neutralisantes par la protéase bactérienne IdeS de
Streptococcus pyogenes" par Mélissa BOU JAOUDEH, Paris